SEC Form DEF 14A filed by Bruker Corporation
$BRKR
Biotechnology: Laboratory Analytical Instruments
Industrials
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/22/2025 | $40.00 | Buy → Neutral | Citigroup |
| 12/19/2024 | $72.00 | Buy | Guggenheim |
| 12/10/2024 | $66.00 | Neutral | UBS |
| 12/5/2024 | $60.00 | Sell → Neutral | Goldman |
| 10/15/2024 | $75.00 | Overweight | Barclays |
| 9/30/2024 | Outperform → Peer Perform | Wolfe Research | |
| 8/28/2024 | $78.00 | Overweight | Wells Fargo |
| 6/3/2024 | $85.00 | Buy | Jefferies |
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
8-K - BRUKER CORP (0001109354) (Filer)
DEFA14A - BRUKER CORP (0001109354) (Filer)
8-K - BRUKER CORP (0001109354) (Filer)
Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00
Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00
UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00
ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with
Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
SC 13G/A - BRUKER CORP (0001109354) (Subject)
Precision in Every Drop: The New MOVE-T Liquid Dairy Analyzer for Enhanced Quality Control Bruker Corporation (NASDAQ:BRKR) today announced the launch of the MOVE-T, a state-of-the-art liquid dairy analyzer designed to elevate quality control standards in the dairy industry. Utilizing advanced Fourier Transform Near-Infrared (FT-NIR) technology, the MOVE-T provides unparalleled precision analyzing raw milk and other liquid dairy products, ensuring superior product quality and consistency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250528642880/en/MOVE-T, a compact liquid analyzer suitable for everything from raw milk to li
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on June 27, 2025 to stockholders of record as of June 16, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscop
Bruker Corporation (NASDAQ:BRKR) today announced that Bruker and 10x Genomics have reached a final settlement to resolve their patent disputes and dismiss multiple litigations, with global patent cross license agreements between the two companies. In connection with the settlement, all ongoing lawsuits and administrative proceedings filed by both companies in several countries, including actions pending in the United States, in Germany, and before the European Unified Patent Court, will be withdrawn. "We're pleased that we have reached a worldwide settlement with 10x, putting an end to all litigation between us," said Mark R. Munch, Ph.D., President of the Bruker Nano Group. "This is a gre
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
4 - BRUKER CORP (0001109354) (Issuer)
Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on June 27, 2025 to stockholders of record as of June 16, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscop
Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's
Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company's earlier outlook and well ahead of consensus. This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net